XFOR vs ABBV vs BMY vs AMGN vs IQV

For growth investors, X4 Pharmaceuticals, Inc.

(XFOR) is the stronger pick with 1273% revenue growth year-over-year, versus -0. 2% for Bristol-Myers Squibb Company (BMY). Bristol-Myers Squibb Company (BMY) offers the better valuation at 16. 6x trailing P/E (9. 0x forward), making it the more compelling value choice. Analysts rate X4 Pharmaceuticals, Inc. (XFOR) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bristol-Myers Squibb Company (BMY) is the cheapest at 16.

6x versus AbbVie Inc. at 96. 1x. On forward P/E, Bristol-Myers Squibb Company is actually cheaper at 9. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IQVIA Holdings Inc. wins at 0. 35x versus Amgen Inc. 's 5. 39x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +123. 7%, compared to -98. 4% for X4 Pharmaceuticals, Inc. (XFOR). Over 10 years, the gap is even starker: ABBV returned +362. 2% versus XFOR's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 14β versus X4 Pharmaceuticals, Inc. 's 2. 35β — meaning XFOR is approximately 1626% more volatile than ABBV relative to the S&P 500. On balance sheet safety, X4 Pharmaceuticals, Inc. (XFOR) carries a lower debt/equity ratio of 41% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), X4 Pharmaceuticals, Inc.

(XFOR) is pulling ahead at 1273% versus -0. 2% for Bristol-Myers Squibb Company (BMY). On earnings-per-share growth, the picture is similar: Bristol-Myers Squibb Company grew EPS 178. 2% year-over-year, compared to -0. 8% for AbbVie Inc.. Over a 3-year CAGR, AMGN leads at 11. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amgen Inc.

(AMGN) is the more profitable company, earning 21. 0% net margin versus -225. 6% for X4 Pharmaceuticals, Inc. — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -247. 4% for XFOR. At the gross margin level — before operating expenses — XFOR leads at 82. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IQVIA Holdings Inc. (IQV) is the more undervalued stock at a PEG of 0. 35x versus Amgen Inc. 's 5. 39x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bristol-Myers Squibb Company (BMY) trades at 9. 0x forward P/E versus 16. 0x for AbbVie Inc. — 6. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for XFOR: 200. 0% to $12. 00.

In this comparison, BMY (4.

3% yield), ABBV (2. 9% yield), AMGN (2. 7% yield) pay a dividend. XFOR, IQV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 14), 2. 9% yield, +362. 2% 10Y return). X4 Pharmaceuticals, Inc. (XFOR) carries a higher beta of 2. 35 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +362. 2%, XFOR: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: XFOR is a small-cap high-growth stock; ABBV is a large-cap quality compounder stock; BMY is a mid-cap deep-value stock; AMGN is a mid-cap quality compounder stock; IQV is a mid-cap quality compounder stock. ABBV, BMY, AMGN pay a dividend while XFOR, IQV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.